Contributor name: LEGEND-HTN team (individuals in order of authorship in the Lancet publication, all authors contributed to these definitions) Marc Suchard @msuchard , Martijn Schuemie @schuemie Harlan Krumholz, Seng Chan You @SCYou , RuiJun Chun @rchen , Nicole Pratt @Nicole_Pratt , Christian Reich @Christian_Reich , Jon Duke @jon_duke , David Madigan @David_Madigan , George Hripcsak @hripcsa , Patrick Ryan @Patrick_Ryan )
Cohort Definition Names:
In the LEGEND-HTN study, we conducted population-level effect estimation studies for the comparative effectiveness of hypertension treatments, using cardiovascular outcomes that were related to intended effects as well as labeled adverse events. These outcome list included:
- Abdominal pain
- Abnormal weight gain
- Abnormal weight loss
- Acute myocardial infarction
- Acute pancreatitis
- Acute renal failure
- All-cause mortality
- Anaphylactoid reaction
- Anemia
- Angioedema
- Anxiety
- Bradycardia
- Cardiac arrhythmia
- Cardiovascular disease
- Cardiovascular-related mortality
- Chest pain or angina
- Kidney disease
- Coronary heart disease
- Cough
- Decreased libido
- Dementia
- Depression
- Diarrhea
- Edema
- End stage renal disease
- Fall
- Gastrointestinal bleeding
- Gout
- Headache
- Heart failure
- Hemorrhagic stroke
- Hepatic failure
- Hospitalization with heart failure
- Hospitalization with preinfarction syndrome
- Hyperkalemia
- Hypokalemia
- Hypomagnesemia
- Hyponatremia
- Hypotension
- Impotence
- Ischemic stroke
- Malignant neoplasm
- Measured renal dysfunction
- Nausea
- Neutropenia or agranulocytosis
- Rash
- Rhabdomyolysis
- Stroke
- Sudden cardiac death
- Syncope
- Thrombocytopenia
- Transient ischemic attack
- Type 2 diabetes mellitus
- Vasculitis
- Venous thromboembolic events
- Vertigo
- Vomiting
- Chronic kidney disease
Logic and description:
The full list of outcomes with descriptions are described in the LEGEND-HTN Git repo as a csv file here (all records where indicationId = ‘Hypertension’): https://github.com/OHDSI/Legend/blob/master/inst/settings/OutcomesOfInterest.csv
All JSON corresponding to these cohorts are available here: there are two sets: LEGEND-HTN outcomes are here: https://github.com/OHDSI/Legend/tree/master/inst/cohorts
Recommended study application: Outcome
Assertion statement: This cohort definition was executed on at least one real person-level observational health data source and resulted in a cohort with at least 1 person.
Citations: These outcome phenotypes have been used in multiple peer-review publications:
Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019 Nov 16;394(10211):1816-1826. doi: 10.1016/S0140-6736(19)32317-7. Epub 2019 Oct 24. PMID: 31668726; PMCID: PMC6924620. https://www.thelancet.com/article/S0140-6736(19)32317-7/fulltext
Hripcsak G, Suchard MA, Shea S, Chen R, You SC, Pratt N, Madigan D, Krumholz HM, Ryan PB, Schuemie MJ. Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. JAMA Intern Med. 2020 Apr 1;180(4):542-551. doi: 10.1001/jamainternmed.2019.7454. PMID: 32065600; PMCID: PMC7042845. Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension
Schuemie MJ, Ryan PB, Pratt N, Chen R, You SC, Krumholz HM, Madigan D, Hripcsak G, Suchard MA. Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study. J Am Med Inform Assoc. 2020 Aug 1;27(8):1268-1277. doi: 10.1093/jamia/ocaa124. Erratum in: J Am Med Inform Assoc. 2021 Jan 15;28(1):196. PMID: 32827027; PMCID: PMC7481033. Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study | Journal of the American Medical Informatics Association | Oxford Academic
Chan You S, Krumholz HM, Suchard MA, Schuemie MJ, Hripcsak G, Chen R, Shea S, Duke J, Pratt N, Reich CG, Madigan D, Ryan PB, Woong Park R, Park S. Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study. Hypertension. 2021 May 5;77(5):1528-1538. doi: 10.1161/HYPERTENSIONAHA.120.16402. Epub 2021 Mar 29. PMID: 33775125; PMCID: PMC8035236. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.16402
Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, Pratt N, Reich CG, Madigan D, You SC, Ryan PB, Hripcsak G. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension. 2021 Sep;78(3):591-603. doi: 10.1161/HYPERTENSIONAHA.120.16667. Epub 2021 Jul 26. PMID: 34304580; PMCID: PMC8363588. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.16667